At Immcell, we actively seek to repurpose, reposition existing therapeutic interventions. Our main efforts lie in late stage repurposing where we seek to prepare therapeutic leads for clinical testing and evaluation. Through the discovery of new uses for approved drugs, Immcell can accelerate the transition from bench to bedside. In using this de-risking strategy we save money, time, avoid potential safety risks and have a higher chance of success.
Working with a number of third level institutions in both Ireland and the UK, we have elucidated the mechanism of action of IAD (Inosine Acedoben Dimepranol) and its derivatives (e.g. Acedoben Dimepranol) using immunoprofiling techniques. Both IAD and Acedoben Dimepranol exhibit immunosuppressive and immunostimulatory properties. In particular, Dippaccba displays a more dominant immunosuppressive effect.
Inosine Acedoben Dimepranol (IAD) is a synthetic purine derivative consisting of the p- acetamidobenzoic acid salt of N, N-dimethyl-amino-2-propanol (DIPPAcBA) and the β polymorph of inosine (1,9-dihydro-9--D-ribofuranosyl-6-H-purin-6-one) in a 3:1 molar ratio. The material has the physical form of a crystalline white powder and the chemical structure is presented as follows:
Figure 1: The chemical structure of Inosine Acedoben Dimepranol (IAD)
IAD differs physico-chemically from its individual components and has biological characteristics separate from the characteristics of the components when used individually. It has also been reported that only the 1:3 ratio of inosine and DIPPAcBA in IAD is synergistic, other ratios not resulting in enhancement of activity.
The inosine component is a natural purine that is present in foodstuffs such as sugar beets, corn and meat. It also found as a product of purine metabolism in varying but small amounts in cells and tissue fluids. Inosine is also a precursor of other essential purine-derived compounds such as purine- nucleotide coenzymes, high-energy phosphate compounds (ATP and GTP) and cyclic purine nucleotides. The p-acetamidobenzoic acid (PAcBA) moiety of IAD is chemically related to p-amino benzoic acid, a naturally occurring metabolite in human tissue. The N, N- dimethyl-amino-2- propanol (DIP) moiety of IAD is a chemically and pharmacologically novel compound.
IAD it is an immuno-pharmacological agent with both immunomodulatory and anti-viral properties. IAD has been prescribed since 1971 for the treatment of cell-mediated immune deficiencies associated with viral infections. The clinical benefits of IAD are thought to result from modulation and activation of the host cellular immune system resulting in an indirect, host-mediated, anti-viral action.
DIP.PAcBA, a p-acetamidobenzoic acid salt of N, N-dimethyl-amino-2-propanol, is major component of the pharmaceutical drug Inosine Acedoben Dimepranol (IAD). The p-acetamidobenzoic acid (PAcBA) moiety is chemically related to p-amino benzoic acid, a naturally occurring metabolite in human tissue, while the N, N- dimethyl-amino-2- propanol (DIP) moiety is a chemically and pharmacologically novel compound.
Immcell has conducted continuous investigations into the mechanism of action of IAD and Dippaccba. These studies culminated in small in vivo clinical trials in order to determine the effect of IAD on the immune system.
Inosine Acedoben Dimepranol has been heavily researched over the last 40 years. The drug was registered in the 80’s for 20 different viral indications in different global markets.Kora Healthcare our sister company has the rights to market IAD in 11 territories. Immcell would like to invest further in the possible expansion of the therapeutic range of IAD.
Acedoben Dimepranol has not been heavily researched. In order to expand the therapeutic range and progress with Acedoben Dimepranol, Immcell is open to discussing potential development regarding same. See Partnering.